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Use of the mice passive protection test 
to evaluate the humoral response in goats 
vaccinated with Sterne 34F2 live spore vaccine
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Abstract 
The Sterne live spore vaccine (34F2) is the most widely used veterinary vaccine against anthrax in animals. Antibody 
responses to several antigens of Bacillus anthracis have been described with a large focus on those against protec-
tive antigen (PA). The focus of this study was to evaluate the protective humoral immune response induced by the 
live spore anthrax vaccine in goats. Boer goats vaccinated twice (week 0 and week 12) with the Sterne live spore 
vaccine and naive goats were used to monitor the anti-PA and toxin neutralizing antibodies at week 4 and week 17 
(after the second vaccine dose) post vaccination. A/J mice were passively immunized with different dilutions of sera 
from immune and naive goats and then challenged with spores of B. anthracis strain 34F2 to determine the protec-
tive capacity of the goat sera. The goat anti-PA ELISA titres indicated significant sero-conversion at week 17 after the 
second doses of vaccine (p = 0.009). Mice receiving undiluted sera from goats given two doses of vaccine (twice 
immunized) showed the highest protection (86%) with only 20% of mice receiving 1:1000 diluted sera surviving lethal 
challenge. The in vitro toxin neutralization assay (TNA) titres correlated to protection of passively immunized A/J 
mice against lethal infection with the vaccine strain Sterne 34F2 spores using immune goat sera up to a 1:10 dilu-
tion  (rs ≥ 0.522, p = 0.046). This study suggests that the passive mouse protection model could be potentially used 
to evaluate the protective immune response in livestock animals vaccinated with the current live vaccine and new 
vaccines.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Anthrax is a zoonotic disease caused by Bacillus anthra-
cis that affects all mammals especially herbivorous mam-
mals [1]. The main virulence factors are encoded by two 
plasmids, pXO1 and pXO2 [2]. The pXO1 encodes for 
the tripartite protein exotoxin (anthrax toxin) that con-
sists of the cell-binding protective antigen (PA), and two 
enzymes known as lethal factor (LF) and edema factor 
(EF) [3]. The pXO2 encodes for the anti-phagocytic poly-
D glutamic acid (PGA) capsule which protects the bacte-
ria against phagocytosis [4].
Lethal toxin (LT) is formed by the binding of LF to PA 
while edema toxin (ET) formation occurs when EF binds 
to PA [2, 3]. The highly immunogenic PA therefore plays 
a central role in the activation of both LT and ET and was 
shown to elicit a protective immune response against 
anthrax in both experimental animals and humans as 
reviewed by Little et  al. [5]. Virulence of B. anthracis is 
also dependent on the presence of the anti-phagocytic 
capsule and the absence of either pXO1 or pXO2 will 
result in attenuation of the organism [6].
The current anthrax veterinary vaccine comprises 
of spores from the live, attenuated B. anthracis 34F2 
strain developed in 1937 by Max Sterne and known as 
the Sterne live spore vaccine [7]. The vaccine is a sta-
ble uncapsulated mutant that produces all three toxin 
components of B. anthracis (PA, LF and EF) whilst still 
providing protective antigens [7, 8]. Humoral immunity 
develops 2–4  weeks after first vaccination and revac-
cination is recommended every 9–12  months (Anthrax 
vaccine leaflet, Onderstepoort Biological Products, 
South Africa, http://www.obpvaccines.co.za) [9]. In vivo 
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assessment of the Sterne vaccine immunity mainly 
involved pathogenicity and efficacy testing during which 
guinea pigs were vaccinated with Sterne live spore vac-
cine and challenged with B. anthracis strain 17 JB (Pas-
teur II strain) [9]. The use of serological techniques for 
the detection of correlates of protection to anthrax vac-
cine was initiated with the search for efficacious human 
vaccines.
Until recently the few studies on the immune response 
induced by the Sterne live spore vaccine in ruminants 
were done by Turnbull et al. [10] and Shakya et al. [11]. 
Ndumnego and Kohler et al. [12] vaccinated Boer goats 
with one or two doses of Sterne 34F2 live spore vaccine 
and challenged them with fully virulent B. anthracis 
spores. All the goats receiving two vaccine doses survived 
virulent challenge whereas 60 and 80% of those vacci-
nated once survived. Sera collected post-challenge from 
these animals were used as the positive controls in this 
study. In this report, we evaluated the humoral immune 
response induced by the live spore anthrax vaccine in 
Boer goats using the anti-PA ELISA, an in  vitro toxin 
neutralization assay (TNA) and a passive protection test 
in A/J-mice as first performed with large wild animals by 
Turnbull et al. [13].
Materials and methods
Sterne live spore vaccine
The Sterne live spore vaccine is produced by Onderste-
poort Biological Products (OBP) in South Africa and 
consists of B. anthracis strain 34F2  (pXO1+,  pXO2−) 
spores suspended in glycerine at a spore concentration of 
6 × 106 per mL.
Experimental animals
Healthy, age-matched female and emasculated male 
naive Boer goats were used for production of immune 
sera. These animals were sourced from livestock farms 
in Pretoria area (Gauteng Province, South Africa), con-
firmed to be PA-reactive antibody negative by ELISA and 
kept at the OBP experimental animal facility. The animals 
were fed pellets and hay with water ad libitum. They were 
dewormed following arrival and kept in a fenced, out-
door facility with concrete floors throughout the trial. 
All goats were kept together for the entire period of the 
experiment.
Six to eight weeks old female A/J mice were used in the 
passive protection test. A/J mice are deficient for the C5 
complement component rendering them highly suscep-
tible to the Sterne live spore vaccine strain [14]. These 
mice were obtained from Jackson Laboratories, USA, and 
maintained in pathogen-free conditions at the labora-
tory animal facility of the University of Pretoria Biomedi-
cal Research Centre (UPBRC) according to the South 
African national standard for the care and use of animals 
for scientific purpose. All studies were approved by the 
animal ethics committee (AEC) of the University of Pre-
toria, South Africa (protocol approval number V083/13) 
and permission was granted (12/11/1/1) by the Depart-
ment of Agriculture, Forestry and Fisheries, South Africa 
under the animals disease act (Act 35 Section 20, 1984).
Vaccination regimen
The experimental group consisted of Boer goats 
(n =  5), immunized twice with the Sterne live spore 
vaccine (6 × 106 per mL). One ml OBP Sterne vaccine 
was administered subcutaneously at week 0 and week 
12 according to the manufacturer’s instruction. A neg-
ative control group of Boer goats (n = 3) received only 
sterile saline (1  mL) instead of vaccine. The animals 
were bled before the initial vaccination (week 0) and 
at week 4 and week 17. Positive control sera (n =  4) 
were sourced from Boer goats which survived chal-
lenge with virulent anthrax spores after two vaccina-
tions with the Sterne live spore vaccine in a previous 
study [12].
Anti‑PA antibody ELISA
Sera collected at weeks 0, 4 and 17 were analysed for PA-
specific antibody using the ELISA as previously described 
by Hahn et al. [15] and Pombo et al. [16] with some mod-
ifications as described by Ndumnego et al. [17]. Endpoint 
titres of individual serum were defined as the reciprocal 
of the highest serum dilution giving an optical density of 
0.1. Titres of < 50 were ascribed an arbitrary value of 0. 
Sera from immune goats (n = 4) that survived a virulent 
B. anthracis challenge and naive goats (n = 3) were used 
as positive and negative controls respectively.
Toxin neutralization assay (TNA)
An in  vitro toxin neutralization assay (TNA) was per-
formed using a MTT [3-(4.5-dimethylthiazol-2-yl)–
2.5-diphenyltetrazolium bromide] in a colorimetric cell 
viability assay with the J774A.1 macrophage cell line 
as previously described by Hering et  al. [18] with slight 
modifications by Ndumnego et  al. [17]. Briefly, serial 
diluted goat serum was incubated with PA and LF (List 
Biological Laboratories, USA) at concentrations of 500 
and 400  ng/mL respectively before addition to over-
night incubated macrophage cells. The following con-
trols were added to each assay: a single dilution series 
of positive serum from a Sterne hyper-immunized goat 
which survived virulent challenge served as positive con-
trol [12], three wells (without cells) with medium and LT 
served as blanks, three wells (with cells) and LT served as 
toxin control and two wells with cells and culture media 
served as medium control. Cell viability was determined 
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by reading the optical density (OD) at 540 nm after the 
addition of the MTT tetrazolium dye. The neutralization 
titre of each serum was calculated by  NT50 =  (sample 
OD −  toxin control OD)/(medium control OD  –  toxin 
control OD) × 100 and expressed as the reciprocal of the 
highest serum dilution neutralizing 50% of the toxins.
Passive transfer of serum and challenge in A/J mice
A/J mice (n =  96) were used in the passive protection 
tests as previously described by Turnbull et  al. [13]. 
Briefly, serum from twice immunized individual goats 
(n  =  5), collected on week 17, were used either undi-
luted or diluted in physiological saline (1:1000, 1:100, 
1:50, 1:10, 1:5). Each of these dilutions were administered 
intraperitoneally (500  µL) to three A/J mice (n =  3 for 
each goat serum) for each dilution from individual goats 
(n = 15). Positive control mice (n = 12, three A/J mice for 
each goat serum) received undiluted sera from immune 
goats (n = 4) that survived a virulent B. anthracis chal-
lenge. Negative control mice (n =  9, three A/J mice for 
each goat serum) received undiluted sera from naïve 
goats (n  =  3) as performed previously [13]. The mice 
were challenged after 24 h by subcutaneous inoculation 
with 1.92  ×  105 spores [13] from Sterne 34F2 vaccine 
strain and monitored for survival over 14 days. Death due 
to anthrax was confirmed by re-isolation of B. anthra-
cis from liver and spleen smear cultures on sheep blood 
agar. Survivors were euthanized by injecting a barbiturate 
overdose and confirmed free of Sterne spores following 
culture of liver and spleen.
Statistics
We compared the immune response in Sterne vaccinated 
goats using ELISA and TNA with the passive protection 
test in mice. The relationship between individual ELISA, 
TNA antibody titres and time of survival was described 
using the Pearson’s correlation coefficient. Differences 
in antibody titres (ELISA and TNA) between points of 
measurement were analysed using a two-tailed (paired) 
Student t test. p values of < 0.05 were considered statis-
tically significant. The survival times for mice receiving 
different goat serum dilutions were analysed using the 
Kaplan–Meier method in SPSS Version 21 (IBM SPSS 
Statistics, USA). Log-rank test was used to compare the 
survival curves of test and control groups. The anti-PA 
and TNA linear plot was done using Sigma Plot (Systat 
software Inc, USA).
Results
Anti‑PA antibody ELISA and TNA
ELISA was performed to determine the serum IgG anti-
body levels against PA from individual sera collected at 
weeks 0, 4 and 17. Serum anti-PA antibody titres were very 
low in naïve animals, both the animals before the first vac-
cination and control animals injected with sterile saline. 
Titers in the latter group remained low until the end of the 
experiment. The anti-PA titres of each individual animal 
before vaccination (week 0), after first vaccination (week 
4) and after second vaccination (week 17) are indicated 
in Figure  1. There was no significant difference in mean 
titres between week 0 and 4 (p = 0.0913) but there were 
significant differences between week 0 and 17 (p = 0.009) 
and between week 4 and 17 (p = 0.019). The goat anti-PA 
ELISA titres indicated significant sero-conversion at week 
17 after the second doses of vaccine (p = 0.009).
An in  vitro TNA was performed to assess toxin neu-
tralizing antibodies in sera of vaccinated goats using 
murine J774A.1 macrophage cell line. Neutralizing anti-
body titres measured by the TNA assay varied among the 
individual animals. There were no detectable neutralizing 
titres in sera collected at week 0 (before vaccination). The 
TNA titres at week 4 were low and goat D6 and D20 did 
not give neutralization titres after the first vaccination. 
All five immune goat sera showed neutralizing activity 
at week 17 after the second vaccine dose (Figure 2). No 
significant differences were found between TNA titres at 
week 0 and 4 (p = 0.218), but there was significant differ-
ence in mean titres between week 0 and 17 (p = 0.004) 
and between week 4 and 17 (p = 0.025).
Passive protection test
A total of 75 A/J mice were passively immunized with 
undiluted and diluted immune sera ranging from 1:1000, 
1:100, 1:50, 1:10 and 1:5 collected at week 17 from indi-
vidual goats immunized with Sterne live spore vaccine. 
The protective effect of the immune sera was assessed 
following challenge with B. anthracis 34F2 spores. The 
level of protection of the immune goat sera was depend-
ent on the dilution used, while sera from the naïve goats 
failed to protect mice (Figure  3). All nine A/J mice that 
received negative (naive) goat sera died within 3 days of 
challenge, whereas all mice (12/12) that received serum 
from the positive controls (Sterne-immunized goats 
surviving lethal anthrax spores challenge) survived for 
14 days (Figure 3).
Mice receiving immune goat sera at higher dilutions 
showed lower survival than those receiving sera at lower 
dilutions. Analysis of the survival curves showed no dif-
ference between the negative control and the 1:1000 
diluted sera group (p = 0.290). However, survival curves 
from sera groups diluted 1:100 or less were significantly 
different from the negative control (p ≤  0.004). For the 
undiluted immune goat sera, 13 of the 15 (87%) mice sur-
vived the challenge and was no different from the posi-
tive control group (p =  0.165). Two mice injected with 
undiluted sera from vaccinated goats D6 and D20 only 
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died on day 12 (euthanized) and 14, respectively (Table 1). 
Both mice were confirmed positive for anthrax by isola-
tion of B. anthracis from the spleen and liver. Mice that 
received undiluted immune serum had a mean survival 
of 13.9 days compared to the mice that received different 
dilutions for which survival ranged between 5 and 12 days 
depending on the dilution (Table  1). The 1:5, 1:10, 1:50, 
1:100 and 1:1000 dilutions had 80, 47, 13, 13 and 20% sur-
vival rates respectively with most of the mice dying within 
the first 5 days (Figure 3; Table 1). There was no difference 
in survival times between 1:5 and the positive control 
groups (p ≥ 0.0829). However, dilution of immune sera by 
1:10 or more afforded significantly less protection to the 
mice when compared to the positive control (p ≤ 0.002).
Comparison of ELISA, TNA and passive protection test
The ELISA and TNA titres of sera from individual goats 
at week 17 (after second vaccine dose) showed no corre-
lation  (rs =  0.404; p  <  0.135). PA antibody measured in 
sera from individual vaccinated goats did not correlate 
with passive protection in A/J mice using either diluted 
or undiluted sera  (rs ≤ 0.487; p ≥ 0.066). Significant posi-
tive correlations between toxin neutralizing antibodies 
and protection of A/J mice were observed following pas-
sive transfer of immune goat sera diluted at 1:5 and 1:10 
respectively (Table 2).
Discussion
Results of this study demonstrate a potential protec-
tive capacity of the humoral response elicited in Sterne 
live spore vaccinated goats using the passive protection 
test in A/J mice. The passive mouse protection model 
can be effectively used to evaluate the immune response 
in livestock animals. A/J-mice were utilized because of 
their known susceptibility to toxigenic but non-encapsu-
lated strains of B. anthracis such as Sterne or STI-1 [19], 
caused by a deficiency of C5 in the complement system 
[14]. A/J mice react in a dose-dependent manner unlike 
CBA/J and BALB/c mice to a challenge with those vac-
cine strains. Passively transferred goat immune sera pro-
tected A/J mice from lethal challenge with protection 
correlated to sera dilution levels. We observed that sera 
from twice immunized goats (goats vaccinated twice with 
Sterne live spore vaccine 12  weeks apart) with neutral-
izing antibody titres ≥  200 afforded robust protection 
against 1.92 × 105 B. anthracis Sterne strain spores chal-
lenge in the A/J mice model (Table  1). The number of 
goats (n = 5) as well as mice (n = 3 per assessed serum 
dilution) used in this study limited statistical power and 
results should be interpreted in this light. As the main 
focus was to investigate protection only the PA-ELISA 
IgG antibody titres in vaccinated and non-vaccinated 




























Figure 1 Anti-protective antigen (PA) antibody titres as detected by ELISA following Sterne live spore vaccination of goats at week 
0 and week 12. Serum samples of individual goats (D5, D6, D20, D29 and D31) were collected and analysed before vaccination (week 0), 4 weeks 
after initial vaccination (week 4) and after the second vaccine dose (week 17). Mean anti-PA antibody titres detected by ELISA of positive control 
(Sterne live spore vaccinated goats) and negative control (naive goats) are indicated in Table 1.
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be investigated in future. However, this study provides 
valuable insight in the potential use of immune assays 
and the passive protection test to measure presumptive 
protection conferred following vaccination with anthrax 
vaccines.
The B. anthracis TNA is a technique designed to meas-
ure the ability of toxin neutralizing antibody to protect 
certain susceptible cell lines from the lethal effects of 
anthrax toxin [20, 21]. TNA is not species dependent and 
has been developed for use with multiple species [18]. 
Here, the TNA titres directly correlated to survival in 
mice with 1:5 and 1:10 diluted immune goat sera in the 
passive protection test (Table  1). The inability to show 
correlation using undiluted sera was likely due to the 
almost uniform survival observed following challenge, 
with the two non-survivors protected for 12 and 14 days 
respectively (Table  1). We noticed that TNA titres of 
just over 200 can confer protection in the passive pro-
tection test performed in this study. Accordingly serum 
from goat D31 provided 100% (3/3) protection to A/J 
mice for undiluted sera (Table 1) despite a relatively low 
TNA antibody level but did not provide protection when 
diluted 1:10; 1:50 and 1:100. This is in line with data from 
guinea pig studies. Reuveny et al. [20] showed that TNA 
titres as low as 220 will provide some level of protection. 
Toxin neutralization titres were absent to low, 4  weeks 
after the first vaccination but were evident at week 17. 
This supports the results published by Ndumnego et  al. 
[12] who showed a strong increase in titres after a second 
vaccination of goats with the same vaccine (34F2).
Our study provides evidence that the mouse pro-
tection model can be effectively used to evaluate the 
immune response of target animals like livestock, thereby 
eliminating the ethical and logistical challenges associ-
ated with large animal trials. It also obviates the need 
of fully virulent B. anthracis strains for the challenge 
and consequent biosafety level specification. This test 
would be beneficial to assess presumptive protective 
capacities of new vaccine formulations against anthrax 
in animals prohibitive to be experimentally challenged 
(valuable livestock, endangered/critical wildlife popula-
tions). Moreover, it could be used to evaluate and moni-
tor the presumptive protective capacity of vaccination 
procedures currently in veterinary use, e.g. to determine 
the herd immunity after a vaccination campaign. In order 
to unambiguously proof the significance of the correla-
tion between the passive mouse protection test and TNA 

























Figure 2 Toxin neutralization antibody titres following Sterne live spore vaccination of goats at week 0 and week 12. Serum samples 
of individual goats (D5, D6, D20, D29 and D31) were collected and analysed before vaccination (week 0), 4 weeks after initial vaccination (week 4) 
and after the second vaccine dose (week 17). Mean toxin neutralization antibody titres of positive control (Sterne live spore vaccinated goats) and 
negative control (naive goats) are indicated in Table 1.
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Figure 3 Kaplan–Meier plots indicating the survival of A/J mice after passive transfer of naïve and immune goat sera at different 
dilutions. For each group (undiluted and diluted), 500 µL of serum from each goat subject (n = 5) were inoculated into three A/J mice (n = 15 for 
each group). Positive control mice (n = 12, three A/J mice per goat) received undiluted sera from immune goats (n = 4) that survived a virulent B. 
anthracis challenge. Negative control mice (n = 9, three A/J mice per goat) received undiluted sera from naïve goats (n = 3). The mice were lethally 
challenged after 24 h with 1.92 × 105 spores per dose from the Sterne 34F2 vaccine strain.
Table 1 Passive protection test results of A/J mice.
a Sera collected at 17 weeks
b Time to death (in days) of non-surviving mice; Mice injected with undiluted and diluted hyper-immune goat sera and challenged with spores from the Sterne 34F2 
vaccine strain 24 h later and immune sera were diluted from 1:5 to 1:1000
c Sera collected from goats (n = 3) receiving sterile saline only; all mice died within 3 days of challenge with B. anthracis Sterne strain
d Sera sourced from goats (n = 4) surviving virulent anthrax spores after two vaccinations with the Sterne live spore vaccine in a previous study [12]
Goat serum Survival (Time to  deathb)
Animal PA‑ELISA (week 0) TNA (week 0) Undiluted sera 1:5 1:10 1:50 1:100 1:1000
D5a 2680 (212) 3410 (0) 3/3 3/3 2/3 (11) 0/3 (4, 4, 4) 1/3 (3, 3) 0/3 (2, 2, 2)
D6a 4190 (380) 1800 (0) 2/3 (12) 3/3 2/3 (5) 0/3 (3, 3, 3) 0/3 (2, 3, 3) 1/3 (2, 3)
D20a 8050 (310) 2530 (0) 2/3 (14) 3/3 1/3 (4, 7) 1/3 (3, 5) 0/3 (3, 3, 12) 0/3 (2, 2, 3)
D29a 7510 (240) 2280 (0) 3/3 2/3 (5) 2/3 (10) 1/3 (3, 5) 1/3 (3, 8) 1/3 (3, 3)
D31a 1450 (220) 240 (0) 3/3 1/3 (4, 7) 0/3 (3, 3, 4) 0/3 (3, 3, 4) 0/3 (3, 3, 4) 1/3 (2, 3)
Negative  controlac
 D13 590 (80) 0 (0) 0/3 (2, 2, 2)
 D39 100 (130) 0 (0) 0/3 (3, 2, 3)
 D77 120 (90) 0 (0) 0/3 (3, 3, 2)
Positive  controld
 8175 39 590 (212) 5870 (0) 3/3
 8182 17 000 (0) 7300 (0) 3/3
 8210 185 500 (173) 17 380 (0) 3/3
 8212 1 223 430 (405) 35 720 (0) 3/3
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various animal species more such data sets are needed. 
Then, one could imagine that in the future TNA titres 
could serve as the correlate for protection also for com-
mercial vaccine production, making the animal challenge 
tests for vaccine batches obsolete.
Certainly, the final proof for the correlation of TNA 
titres and protection would need appropriate lethal chal-
lenge experiments with various animal species. As this 
approach is, correctly, considered unethical such data 
will have to be collected from further small scale experi-
ments and, where possible, from epidemiological data of 
the veterinary field usage of commercial vaccines. For the 
latter it would be helpful to monitor by TNA the actual 
immune responses in various target animals.
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